hdit101
mAbexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 15, 2019 (NCT04165122)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Herpes simplex virus (type 1 / strain F)Immunity, passive
Herpes simplex virus (type 1 / strain F) immunity, passive
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04539483 | Phase 2 | Oct 8, 2020 | Heidelberg ImmunoTherapeutics GmbH |
| NCT04165122 | Phase 2 | Nov 15, 2019 | Heidelberg ImmunoTherapeutics GmbH |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Heidelberg ImmunoTherapeutics GmbH | For profit | 2 | 2 | 1 | 2019 |
1 organizations
Page 1 / 1